When biotech proteins go off-patent

This publication has 12 references indexed in Scilit:

• Micelle-Associated Protein in Epoetin Formulations: A Risk Factor for Immunogenicity?
  Pharmaceutical Research, 2003
• Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis
  The Lancet, 2003
• ‘Generic’ or ‘follow-on’ biologics: scientific considerations and safety issues
  Expert Opinion on Biological Therapy, 2003
• Immunogenicity of therapeutic proteins: Clinical implications and future prospects
  Published by Elsevier ,2002
• Immunogenicity of rDNA-derived pharmaceuticals
  Trends in Pharmacological Sciences, 2002
• Bioequivalence and the immunogenicity of biopharmaceuticals
  Nature Reviews Drug Discovery, 2002
• Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant Erythropoietin
  New England Journal of Medicine, 2002
• Crossreactivity of mimotopes and peptide homologues of a sequential epitope with a monoclonal antibody does not predict crossreactive immunogenicity
  Vaccine, 1999
• The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model
  Diabetologia, 1994
• Mapping of Linear Antigenic Sites on the S Glycoprotein of a Neurotropic Murine Coronavirus with Synthetic Peptides: A Combination of Nine Prediction Algorithms Fails To Identify Relevant Epitopes and Peptide Immunogenicity Is Drastically Influenced by the Nature of the Protein Carrier
  Virology, 1994